{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:22:51Z","timestamp":1787030571602,"version":"build-2736575974"},"reference-count":53,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15072","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:03:48Z","timestamp":1746169428000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Sintilimab\u2011induced acute erosive hemorrhagic gastritis as an adverse reaction of third\u2011line therapy in a nasopharyngeal carcinoma patient: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Wenqiang","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lv","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyue","family":"Yang","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyuan","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637002, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Feng","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ni","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Bai","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[{"name":"Departmant of Oncology, Mianyang Central Hospital, Mianyang, Sichuan 621000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"key20250611125705_b1-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","article-title":"Immune checkpoint inhibitors: A promising anticancer therapy","volume":"25","author":"Singh","year":"2020","journal-title":"Drug Discov Today"},{"key":"key20250611125705_b2-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.3390\/ijerph20042926","article-title":"Nasopharyngeal carcinoma burden and its attributable risk factors in China: Estimates and forecasts from 1990 to 2050","volume":"20","author":"Zhang","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"key20250611125705_b3-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4143\/crt.2021.101","article-title":"Long-term survivals, toxicities and the role of chemotherapy in Early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: A retrospective study with 15-Year Follow-up","volume":"54","author":"Wang","year":"2022","journal-title":"Cancer Res Treat"},{"key":"key20250611125705_b4-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"103244","DOI":"10.1016\/j.critrevonc.2021.103244","article-title":"Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis","volume":"160","author":"Bongiovanni","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20250611125705_b5-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): An updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet"},{"key":"key20250611125705_b6-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"key20250611125705_b7-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250611125705_b8-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial","volume":"9","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"key20250611125705_b9-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20250611125705_b10-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.molmed.2020.10.004","article-title":"PD-L1 and B7-1 Cis-Interaction: New mechanisms in immune checkpoints and immunotherapies","volume":"27","author":"Nishimura","year":"2021","journal-title":"Trends Mol Med"},{"key":"key20250611125705_b11-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A promising Anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"key20250611125705_b12-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-020-00250-z","article-title":"Recent updates on Sintilimab in solid tumor immunotherapy","volume":"8","author":"Liu","year":"2020","journal-title":"Biomark Res"},{"key":"key20250611125705_b13-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20250611125705_b14-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.09.028","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as First-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, Double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20250611125705_b15-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/S1556-0864(21)01938-9","article-title":"Sintilimab plus platinum and gemcitabine as First-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, Double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250611125705_b16-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"key20250611125705_b17-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e003635","DOI":"10.1136\/jitc-2021-003635","article-title":"Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: Early results of a phase 2 study","volume":"10","author":"Jiang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20250611125705_b18-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"840916","DOI":"10.3389\/fimmu.2022.840916","article-title":"Upper gastrointestinal tract IrAEs: A case report about Sintilimab-induced acute erosive hemorrhagic gastritis","volume":"13","author":"Ai","year":"2022","journal-title":"Front Immunol"},{"key":"key20250611125705_b19-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.amjms.2022.02.010","article-title":"Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma","volume":"364","author":"Elmasry","year":"2022","journal-title":"Am J Med Sci"},{"key":"key20250611125705_b20-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","article-title":"Acute hemorrhagic gastritis after nivolumab treatment","volume":"86","author":"Kobayashi","year":"2017","journal-title":"Gastrointest Endosc"},{"key":"key20250611125705_b21-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41395-018-0366-3","article-title":"Checkpoint Inhibitor-induced hemorrhagic gastritis with pembrolizumab","volume":"114","author":"Rao","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key20250611125705_b22-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e00402","DOI":"10.14309\/crj.0000000000000402","article-title":"Combination checkpoint inhibitor-induced hemorrhagic gastritis","volume":"7","author":"Bazarbashi","year":"2020","journal-title":"ACG Case Rep J"},{"key":"key20250611125705_b23-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20250611125705_b24-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key20250611125705_b25-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"key20250611125705_b26-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20250611125705_b27-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1001\/jamaoncol.2021.5009","article-title":"Immunotherapy adverse effects","volume":"7","author":"Brown","year":"2021","journal-title":"JAMA Oncol"},{"key":"key20250611125705_b28-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40257-019-00427-9","article-title":"Immune checkpoint inhibitors and beyond: An overview of Immune-based therapies in merkel cell carcinoma","volume":"20","author":"Samimi","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"key20250611125705_b29-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): Diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"key20250611125705_b30-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3348\/kjr.2020.1299","article-title":"Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know","volume":"22","author":"Russo","year":"2021","journal-title":"Korean J Radiol"},{"key":"key20250611125705_b31-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"E982","DOI":"10.1055\/a-1839-4303","article-title":"Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review","volume":"10","author":"Sugiyama","year":"2022","journal-title":"Endosc Int Open"},{"key":"key20250611125705_b32-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/jgh3.12657","article-title":"Immune checkpoint inhibitor-related gastritis in a patient with metastatic melanoma","volume":"5","author":"Sugiyama","year":"2021","journal-title":"JGH Open"},{"key":"key20250611125705_b33-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s10620-020-06441-w","article-title":"Clinical, endoscopic, and pathological characteristics of immune checkpoint Inhibitor-induced gastroenterocolitis","volume":"66","author":"Hayashi","year":"2021","journal-title":"Dig Dis Sci"},{"key":"key20250611125705_b34-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"key20250611125705_b35-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":"Alpha-CTLA-4 mAb-associated panenteritis: A histologic and immunohistochemical analysis","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"key20250611125705_b36-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/PAS.0000000000001730","article-title":"Histopathology of gastrointestinal Immune-related adverse events: A practical review for the practicing pathologist","volume":"46","author":"Zhang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"key20250611125705_b37-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3748\/wjg.v30.i14.1941","article-title":"Immune checkpoint inhibitor-associated gastritis: Patterns and management","volume":"30","author":"Lin","year":"2024","journal-title":"World J Gastroenterol"},{"key":"key20250611125705_b38-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"key20250611125705_b39-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12029-024-01067-x","article-title":"Clinical characteristics and outcomes of pembrolizumab induced gastritis: A systematic review of the literature","volume":"55","author":"Lei","year":"2024","journal-title":"J Gastrointestinal Cancer"},{"key":"key20250611125705_b40-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5858\/arpa.2019-0700-OA","article-title":"Immune checkpoint Inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, helicobacter pylori gastritis and celiac disease","volume":"145","author":"Irshaid","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"key20250611125705_b41-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"key20250611125705_b42-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"153","DOI":"10.32074\/1591-951X-163","article-title":"Gastritis: Update on etiological features and histological practical approach","volume":"112","author":"Pennelli","year":"2020","journal-title":"Pathologica"},{"key":"key20250611125705_b43-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.3747\/co.27.6163","article-title":"Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma","volume":"27","author":"Kim","year":"2020","journal-title":"Curr Oncol"},{"key":"key20250611125705_b44-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/v16030452","article-title":"Cytomegalovirus diseases of the gastrointestinal tract in immunocompetent patients: A narrative review","volume":"16","author":"Yeh","year":"2024","journal-title":"Viruses"},{"key":"key20250611125705_b45-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.ctrv.2022.102452","article-title":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias","volume":"110","author":"Kfoury","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"key20250611125705_b46-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e006500","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: A systematic review","volume":"11","author":"Barron","year":"2023","journal-title":"J Immunother Cancer"},{"key":"key20250611125705_b47-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"key20250611125705_b48-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"104420","DOI":"10.1016\/j.critrevonc.2024.104420","article-title":"The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies","volume":"200","author":"Daher","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20250611125705_b49-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"e000463","DOI":"10.1136\/jitc-2019-000463","article-title":"Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency","volume":"8","author":"Pang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20250611125705_b50-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key20250611125705_b51-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-related adverse events associated with immune checkpoint inhibitors for treatment of Non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20250611125705_b52-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"key":"key20250611125705_b53-ol-30-1-15072","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.3960","article-title":"Immune checkpoint inhibitor rechallenge after Immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T05:57:11Z","timestamp":1749621431000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15072","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]}}}